aluates Reports

$ 0.0

Automative

Global Biosimilar Drug Market Research Report 2026

Published Date: 2026-02-03

Report Code: QYRE-Auto-16A2554

Global Biosimilar Drug Market Insights and Forecast to 2028

BUY CHAPTERS

Global Biosimilar Drug Market Research Report 2026

Code: QYRE-Auto-16A2554

Report

2026-02-03

Pages:111

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Amgen Inc

Eli Lilly

CP Guojian Pharma

Biotech Pharma

Celgen Pharma

Henlius

Sandoz Inc

Changchun High Tech

Innovent

Biosimilar Drug Market

The global Biosimilar Drug market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Biosimilar Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product"s patent expires.

In China, Biosimilar Drug key players include CP Guojian Pharma, Biotech Pharma, Celgen Pharma, etc. Global top three manufacturers hold a share over 70%.

East China is the largest market, with a share over 70%, followed by North China, with a share about 15 percent.

In terms of product, Tablets is the largest segment, with a share over 65%. And in terms of application, the largest application is Ankylosing Spondylitis, followed by Rheumatoid Arthrtis, Tumor, Cardiovascular, etc.

This report delivers a comprehensive overview of the global Biosimilar Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Biosimilar Drug. The Biosimilar Drug market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Biosimilar Drug market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Biosimilar Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Biosimilar Drug Market Report

Report Metric	Details
Report Name	Biosimilar Drug Market
Segment by Type	Injection Tablets Other Types
by Application	Ankylosing Spondylitis Tumor Rheumatoid Arthrtis Cardiovascular Other Application
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	CP Guojian Pharma, Biotech Pharma, Celgen Pharma, Henlius, Amgen, Eli Lilly, Sandoz, Changchun High Tech, Innovent
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Biosimilar Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Biosimilar Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

What is the market share of major companies in Biosimilar Drug Market?

Ans: Global top three manufacturers hold a share over 70%.

What is the Biosimilar Drug Market share by region?

Ans: East China is the largest market, with a share over 70%, followed by North China, with a share about 15 percent.

What is the Biosimilar Drug Market share by type?

Ans: In terms of product, Tablets is the largest segment, with a share over 65%.

Who are the main players in the Biosimilar Drug Market report?

Ans: The main players in the Biosimilar Drug Market are CP Guojian Pharma, Biotech Pharma, Celgen Pharma, Henlius, Amgen, Eli Lilly, Sandoz, Changchun High Tech, Innovent

What are the Application segmentation covered in the Biosimilar Drug Market report?

Ans: The Applications covered in the Biosimilar Drug Market report are Ankylosing Spondylitis, Tumor, Rheumatoid Arthrtis, Cardiovascular, Other Application

What are the Type segmentation covered in the Biosimilar Drug Market report?

Ans: The Types covered in the Biosimilar Drug Market report are Injection, Tablets, Other Types

1 Biosimilar Drug Market Overview

1.1 Product Definition

1.2 Biosimilar Drug by Type

1.2.1 Global Biosimilar Drug Market Value by Type: 2025 vs 2032

1.2.2 Injection

1.2.3 Tablets

1.2.4 Other Types

1.3 Biosimilar Drug by Application

1.3.1 Global Biosimilar Drug Market Value by Application: 2025 vs 2032

1.3.2 Ankylosing Spondylitis

1.3.3 Tumor

1.3.4 Rheumatoid Arthrtis

1.3.5 Cardiovascular

1.3.6 Other Application

1.4 Global Biosimilar Drug Market Size Estimates and Forecasts

1.4.1 Global Biosimilar Drug Revenue 2021–2032

1.4.2 Global Biosimilar Drug Sales 2021–2032

1.4.3 Global Biosimilar Drug Market Average Price (2021–2032)

1.5 Assumptions and Limitations

2 Biosimilar Drug Market Competition by Manufacturers

2.1 Global Biosimilar Drug Sales Market Share by Manufacturers (2021–2026)

2.2 Global Biosimilar Drug Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Biosimilar Drug Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Biosimilar Drug, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Biosimilar Drug, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Biosimilar Drug, Product Types and Applications

2.7 Global Key Manufacturers of Biosimilar Drug, Date of Entry into the Industry

2.8 Global Biosimilar Drug Market Competitive Situation and Trends

2.8.1 Global Biosimilar Drug Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Biosimilar Drug Players Market Share by Revenue

2.8.3 Global Biosimilar Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Biosimilar Drug Market Scenario by Region

3.1 Global Biosimilar Drug Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Biosimilar Drug Sales by Region: 2021–2032

3.2.1 Global Biosimilar Drug Sales by Region: 2021–2026

3.2.2 Global Biosimilar Drug Sales by Region: 2027–2032

3.3 Global Biosimilar Drug Revenue by Region: 2021–2032

3.3.1 Global Biosimilar Drug Revenue by Region: 2021–2026

3.3.2 Global Biosimilar Drug Revenue by Region: 2027–2032

3.4 North America Biosimilar Drug Market Facts & Figures by Country

3.4.1 North America Biosimilar Drug Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Biosimilar Drug Sales by Country (2021–2032)

3.4.3 North America Biosimilar Drug Revenue by Country (2021–2032)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Biosimilar Drug Market Facts & Figures by Country

3.5.1 Europe Biosimilar Drug Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Biosimilar Drug Sales by Country (2021–2032)

3.5.3 Europe Biosimilar Drug Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Biosimilar Drug Market Facts & Figures by Region

3.6.1 Asia Pacific Biosimilar Drug Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Biosimilar Drug Sales by Region (2021–2032)

3.6.3 Asia Pacific Biosimilar Drug Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Biosimilar Drug Market Facts & Figures by Country

3.7.1 Latin America Biosimilar Drug Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Biosimilar Drug Sales by Country (2021–2032)

3.7.3 Latin America Biosimilar Drug Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Biosimilar Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Biosimilar Drug Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Biosimilar Drug Sales by Country (2021–2032)

3.8.3 Middle East and Africa Biosimilar Drug Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Biosimilar Drug Sales by Type (2021–2032)

4.1.1 Global Biosimilar Drug Sales by Type (2021–2026)

4.1.2 Global Biosimilar Drug Sales by Type (2027–2032)

4.1.3 Global Biosimilar Drug Sales Market Share by Type (2021–2032)

4.2 Global Biosimilar Drug Revenue by Type (2021–2032)

4.2.1 Global Biosimilar Drug Revenue by Type (2021–2026)

4.2.2 Global Biosimilar Drug Revenue by Type (2027–2032)

4.2.3 Global Biosimilar Drug Revenue Market Share by Type (2021–2032)

4.3 Global Biosimilar Drug Price by Type (2021–2032)

5 Segment by Application

5.1 Global Biosimilar Drug Sales by Application (2021–2032)

5.1.1 Global Biosimilar Drug Sales by Application (2021–2026)

5.1.2 Global Biosimilar Drug Sales by Application (2027–2032)

5.1.3 Global Biosimilar Drug Sales Market Share by Application (2021–2032)

5.2 Global Biosimilar Drug Revenue by Application (2021–2032)

5.2.1 Global Biosimilar Drug Revenue by Application (2021–2026)

5.2.2 Global Biosimilar Drug Revenue by Application (2027–2032)

5.2.3 Global Biosimilar Drug Revenue Market Share by Application (2021–2032)

5.3 Global Biosimilar Drug Price by Application (2021–2032)

6 Key Companies Profiled

6.1 CP Guojian Pharma

6.1.1 CP Guojian Pharma Company Information

6.1.2 CP Guojian Pharma Description and Business Overview

6.1.3 CP Guojian Pharma Biosimilar Drug Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 CP Guojian Pharma Biosimilar Drug Product Portfolio

6.1.5 CP Guojian Pharma Recent Developments/Updates

6.2 Biotech Pharma

6.2.1 Biotech Pharma Company Information

6.2.2 Biotech Pharma Description and Business Overview

6.2.3 Biotech Pharma Biosimilar Drug Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Biotech Pharma Biosimilar Drug Product Portfolio

6.2.5 Biotech Pharma Recent Developments/Updates

6.3 Celgen Pharma

6.3.1 Celgen Pharma Company Information

6.3.2 Celgen Pharma Description and Business Overview

6.3.3 Celgen Pharma Biosimilar Drug Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Celgen Pharma Biosimilar Drug Product Portfolio

6.3.5 Celgen Pharma Recent Developments/Updates

6.4 Henlius

6.4.1 Henlius Company Information

6.4.2 Henlius Description and Business Overview

6.4.3 Henlius Biosimilar Drug Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Henlius Biosimilar Drug Product Portfolio

6.4.5 Henlius Recent Developments/Updates

6.5 Amgen

6.5.1 Amgen Company Information

6.5.2 Amgen Description and Business Overview

6.5.3 Amgen Biosimilar Drug Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Amgen Biosimilar Drug Product Portfolio

6.5.5 Amgen Recent Developments/Updates

6.6 Eli Lilly

6.6.1 Eli Lilly Company Information

6.6.2 Eli Lilly Description and Business Overview

6.6.3 Eli Lilly Biosimilar Drug Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Eli Lilly Biosimilar Drug Product Portfolio

6.6.5 Eli Lilly Recent Developments/Updates

6.7 Sandoz

6.7.1 Sandoz Company Information

6.7.2 Sandoz Description and Business Overview

6.7.3 Sandoz Biosimilar Drug Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Sandoz Biosimilar Drug Product Portfolio

6.7.5 Sandoz Recent Developments/Updates

6.8 Changchun High Tech

6.8.1 Changchun High Tech Company Information

6.8.2 Changchun High Tech Description and Business Overview

6.8.3 Changchun High Tech Biosimilar Drug Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Changchun High Tech Biosimilar Drug Product Portfolio

6.8.5 Changchun High Tech Recent Developments/Updates

6.9 Innovent

6.9.1 Innovent Company Information

6.9.2 Innovent Description and Business Overview

6.9.3 Innovent Biosimilar Drug Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Innovent Biosimilar Drug Product Portfolio

6.9.5 Innovent Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Biosimilar Drug Industry Chain Analysis

7.2 Biosimilar Drug Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Biosimilar Drug Production Mode & Process Analysis

7.4 Biosimilar Drug Sales and Marketing

7.4.1 Biosimilar Drug Sales Channels

7.4.2 Biosimilar Drug Distributors

7.5 Biosimilar Drug Customer Analysis

8 Biosimilar Drug Market Dynamics

8.1 Biosimilar Drug Industry Trends

8.2 Biosimilar Drug Market Drivers

8.3 Biosimilar Drug Market Challenges

8.4 Biosimilar Drug Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Amgen Inc

Eli Lilly

CP Guojian Pharma

Biotech Pharma

Celgen Pharma

Henlius

Sandoz Inc

Changchun High Tech

Innovent

List of Tables

Table 1. Global Biosimilar Drug Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Biosimilar Drug Market Value by Application (US$ Million), 2025 vs 2032

Table 3. Global Biosimilar Drug Market Competitive Situation by Manufacturers in 2025

Table 4. Global Biosimilar Drug Sales (K Dose) of Key Manufacturers (2021–2026)

Table 5. Global Biosimilar Drug Sales Market Share by Manufacturers (2021–2026)

Table 6. Global Biosimilar Drug Revenue (US$ Million) by Manufacturers (2021–2026)

Table 7. Global Biosimilar Drug Revenue Share by Manufacturers (2021–2026)

Table 8. Global Market Biosimilar Drug Average Price (USD/Dose) of Key Manufacturers (2021–2026)

Table 9. Global Key Players of Biosimilar Drug, Industry Ranking, 2023 vs 2024 vs 2025

Table 10. Global Key Manufacturers of Biosimilar Drug, Manufacturing Sites and Headquarters

Table 11. Global Key Manufacturers of Biosimilar Drug, Product Types and Applications

Table 12. Global Key Manufacturers of Biosimilar Drug, Date of Entry into the Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Biosimilar Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Biosimilar Drug Revenue, 2025

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Biosimilar Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global Biosimilar Drug Sales by Region (K Dose), 2021–2026

Table 18. Global Biosimilar Drug Sales Market Share by Region (2021–2026)

Table 19. Global Biosimilar Drug Sales by Region (K Dose), 2027–2032

Table 20. Global Biosimilar Drug Sales Market Share by Region (2027–2032)

Table 21. Global Biosimilar Drug Revenue by Region (US$ Million), 2021–2026

Table 22. Global Biosimilar Drug Revenue Market Share by Region (2021–2026)

Table 23. Global Biosimilar Drug Revenue by Region (US$ Million), 2027–2032

Table 24. Global Biosimilar Drug Revenue Market Share by Region (2027–2032)

Table 25. North America Biosimilar Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 26. North America Biosimilar Drug Sales by Country (K Dose), 2021–2026

Table 27. North America Biosimilar Drug Sales by Country (K Dose), 2027–2032

Table 28. North America Biosimilar Drug Revenue by Country (US$ Million), 2021–2026

Table 29. North America Biosimilar Drug Revenue by Country (US$ Million), 2027–2032

Table 30. Europe Biosimilar Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 31. Europe Biosimilar Drug Sales by Country (K Dose), 2021–2026

Table 32. Europe Biosimilar Drug Sales by Country (K Dose), 2027–2032

Table 33. Europe Biosimilar Drug Revenue by Country (US$ Million), 2021–2026

Table 34. Europe Biosimilar Drug Revenue by Country (US$ Million), 2027–2032

Table 35. Asia Pacific Biosimilar Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 36. Asia Pacific Biosimilar Drug Sales by Region (K Dose), 2021–2026

Table 37. Asia Pacific Biosimilar Drug Sales by Region (K Dose), 2027–2032

Table 38. Asia Pacific Biosimilar Drug Revenue by Region (US$ Million), 2021–2026

Table 39. Asia Pacific Biosimilar Drug Revenue by Region (US$ Million), 2027–2032

Table 40. Latin America Biosimilar Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 41. Latin America Biosimilar Drug Sales by Country (K Dose), 2021–2026

Table 42. Latin America Biosimilar Drug Sales by Country (K Dose), 2027–2032

Table 43. Latin America Biosimilar Drug Revenue by Country (US$ Million), 2021–2026

Table 44. Latin America Biosimilar Drug Revenue by Country (US$ Million), 2027–2032

Table 45. Middle East and Africa Biosimilar Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 46. Middle East and Africa Biosimilar Drug Sales by Country (K Dose), 2021–2026

Table 47. Middle East and Africa Biosimilar Drug Sales by Country (K Dose), 2027–2032

Table 48. Middle East and Africa Biosimilar Drug Revenue by Country (US$ Million), 2021–2026

Table 49. Middle East and Africa Biosimilar Drug Revenue by Country (US$ Million), 2027–2032

Table 50. Global Biosimilar Drug Sales (K Dose) by Type (2021–2026)

Table 51. Global Biosimilar Drug Sales (K Dose) by Type (2027–2032)

Table 52. Global Biosimilar Drug Sales Market Share by Type (2021–2026)

Table 53. Global Biosimilar Drug Sales Market Share by Type (2027–2032)

Table 54. Global Biosimilar Drug Revenue (US$ Million) by Type (2021–2026)

Table 55. Global Biosimilar Drug Revenue (US$ Million) by Type (2027–2032)

Table 56. Global Biosimilar Drug Revenue Market Share by Type (2021–2026)

Table 57. Global Biosimilar Drug Revenue Market Share by Type (2027–2032)

Table 58. Global Biosimilar Drug Price (USD/Dose) by Type (2021–2026)

Table 59. Global Biosimilar Drug Price (USD/Dose) by Type (2027–2032)

Table 60. Global Biosimilar Drug Sales (K Dose) by Application (2021–2026)

Table 61. Global Biosimilar Drug Sales (K Dose) by Application (2027–2032)

Table 62. Global Biosimilar Drug Sales Market Share by Application (2021–2026)

Table 63. Global Biosimilar Drug Sales Market Share by Application (2027–2032)

Table 64. Global Biosimilar Drug Revenue (US$ Million) by Application (2021–2026)

Table 65. Global Biosimilar Drug Revenue (US$ Million) by Application (2027–2032)

Table 66. Global Biosimilar Drug Revenue Market Share by Application (2021–2026)

Table 67. Global Biosimilar Drug Revenue Market Share by Application (2027–2032)

Table 68. Global Biosimilar Drug Price (USD/Dose) by Application (2021–2026)

Table 69. Global Biosimilar Drug Price (USD/Dose) by Application (2027–2032)

Table 70. CP Guojian Pharma Company Information

Table 71. CP Guojian Pharma Description and Business Overview

Table 72. CP Guojian Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 73. CP Guojian Pharma Biosimilar Drug Product

Table 74. CP Guojian Pharma Recent Developments/Updates

Table 75. Biotech Pharma Company Information

Table 76. Biotech Pharma Description and Business Overview

Table 77. Biotech Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 78. Biotech Pharma Biosimilar Drug Product

Table 79. Biotech Pharma Recent Developments/Updates

Table 80. Celgen Pharma Company Information

Table 81. Celgen Pharma Description and Business Overview

Table 82. Celgen Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 83. Celgen Pharma Biosimilar Drug Product

Table 84. Celgen Pharma Recent Developments/Updates

Table 85. Henlius Company Information

Table 86. Henlius Description and Business Overview

Table 87. Henlius Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 88. Henlius Biosimilar Drug Product

Table 89. Henlius Recent Developments/Updates

Table 90. Amgen Company Information

Table 91. Amgen Description and Business Overview

Table 92. Amgen Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 93. Amgen Biosimilar Drug Product

Table 94. Amgen Recent Developments/Updates

Table 95. Eli Lilly Company Information

Table 96. Eli Lilly Description and Business Overview

Table 97. Eli Lilly Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 98. Eli Lilly Biosimilar Drug Product

Table 99. Eli Lilly Recent Developments/Updates

Table 100. Sandoz Company Information

Table 101. Sandoz Description and Business Overview

Table 102. Sandoz Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 103. Sandoz Biosimilar Drug Product

Table 104. Sandoz Recent Developments/Updates

Table 105. Changchun High Tech Company Information

Table 106. Changchun High Tech Description and Business Overview

Table 107. Changchun High Tech Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 108. Changchun High Tech Biosimilar Drug Product

Table 109. Changchun High Tech Recent Developments/Updates

Table 110. Innovent Company Information

Table 111. Innovent Description and Business Overview

Table 112. Innovent Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)

Table 113. Innovent Biosimilar Drug Product

Table 114. Innovent Recent Developments/Updates

Table 115. Key Raw Materials Lists

Table 116. Raw Materials Key Suppliers Lists

Table 117. Biosimilar Drug Distributors List

Table 118. Biosimilar Drug Customers List

Table 119. Biosimilar Drug Market Trends

Table 120. Biosimilar Drug Market Drivers

Table 121. Biosimilar Drug Market Challenges

Table 122. Biosimilar Drug Market Restraints

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Product Picture of Biosimilar Drug

Figure 2. Global Biosimilar Drug Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Biosimilar Drug Market Share by Type: 2025 & 2032

Figure 4. Injection Product Picture

Figure 5. Tablets Product Picture

Figure 6. Other Types Product Picture

Figure 7. Global Biosimilar Drug Market Value by Application (US$ Million), 2021–2032

Figure 8. Global Biosimilar Drug Market Share by Application: 2025 & 2032

Figure 9. Ankylosing Spondylitis

Figure 10. Tumor

Figure 11. Rheumatoid Arthrtis

Figure 12. Cardiovascular

Figure 13. Other Application

Figure 14. Global Biosimilar Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 15. Global Biosimilar Drug Market Size (US$ Million), 2021–2032

Figure 16. Global Biosimilar Drug Sales (K Dose), 2021–2032

Figure 17. Global Biosimilar Drug Average Price (USD/Dose), 2021–2032

Figure 18. Biosimilar Drug Report Years Considered

Figure 19. Biosimilar Drug Sales Share by Manufacturers in 2025

Figure 20. Global Biosimilar Drug Revenue Share by Manufacturers in 2025

Figure 21. Top 5 and Top 10 Global Biosimilar Drug Players: Market Share by Revenue in Biosimilar Drug in 2025

Figure 22. Biosimilar Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 23. Global Biosimilar Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 24. North America Biosimilar Drug Sales Market Share by Country (2021–2032)

Figure 25. North America Biosimilar Drug Revenue Market Share by Country (2021–2032)

Figure 26. U.S. Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 27. Canada Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 28. Europe Biosimilar Drug Sales Market Share by Country (2021–2032)

Figure 29. Europe Biosimilar Drug Revenue Market Share by Country (2021–2032)

Figure 30. Germany Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 31. France Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 32. U.K. Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 33. Italy Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 34. Russia Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 35. Asia Pacific Biosimilar Drug Sales Market Share by Region (2021–2032)

Figure 36. Asia Pacific Biosimilar Drug Revenue Market Share by Region (2021–2032)

Figure 37. China Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. Japan Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. South Korea Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. India Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. Australia Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. China Taiwan Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Indonesia Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 44. Thailand Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 45. Malaysia Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Latin America Biosimilar Drug Sales Market Share by Country (2021–2032)

Figure 47. Latin America Biosimilar Drug Revenue Market Share by Country (2021–2032)

Figure 48. Mexico Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. Brazil Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. Argentina Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. Middle East and Africa Biosimilar Drug Sales Market Share by Country (2021–2032)

Figure 52. Middle East and Africa Biosimilar Drug Revenue Market Share by Country (2021–2032)

Figure 53. Turkey Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. Saudi Arabia Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. UAE Biosimilar Drug Revenue Growth Rate (US$ Million), 2021–2032

Figure 56. Global Sales Market Share of Biosimilar Drug by Type (2021–2032)

Figure 57. Global Revenue Market Share of Biosimilar Drug by Type (2021–2032)

Figure 58. Global Biosimilar Drug Price (USD/Dose) by Type (2021–2032)

Figure 59. Global Sales Market Share of Biosimilar Drug by Application (2021–2032)

Figure 60. Global Revenue Market Share of Biosimilar Drug by Application (2021–2032)

Figure 61. Global Biosimilar Drug Price (USD/Dose) by Application (2021–2032)

Figure 62. Biosimilar Drug Value Chain

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Bevacizumab Biosimilar Market

Glycosylated Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cetuximab Biosimilar Market Research Report 2025

Global Filgrastim and Biosimilars Market Research Report 2024

Generic and Biosimilar Pharmaceuticals Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Recombinant Glycosylated Proteins Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Trastuzumab Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Infliximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Adalimumab Infliximab And Etanercept Biosimilars Market Research Report 2024

Biosimilar of Remicade Market

Global Herceptin Biosimilar Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions